Natural history of hepatitis C virus infection

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 128-132

  Mondelli, Mario U ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cofactors; Genetic variability; Hepatitis C virus; Immune response; Natural history

Indexed keywords

CELLULAR IMMUNITY; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HOST RESISTANCE; HUMAN; INFECTION RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PERSISTENT VIRUS INFECTION; PROGNOSIS; REVIEW; VIRUS TRANSMISSION;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0141728356     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Houghton, M. In: Hagedorn C, Rice C, eds. The hepatitis C viruses. Berlin: Springer, 2000: 327.
2. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
3. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-9.
4. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-9.
5. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis; 1997; 176: 859-66.
6. Scognamiglio P, Accapezzato D, Casciaro MA, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162: 6681-9.
7. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
8. Shata MTM, Tricoche N, Perkus M, et al. Exposure to low infective dose of HCV induces cellular immune responses without detectable viremia or seroconversion in chimpanzees. Abstract presented at the 9th International Meeting on Hepatitis C Virus and Related Viruses, San Diego, 2002.
9. Alter HJ, Conry-Cantelena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26 (Suppl.): S29-33.
10. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000; 284: 450-6.
11. Seef LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis; a National Heart, Lung and Blood Institute collaborative study. Hepatology 2001; 33: 455-63.
12. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
13. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997; 90: 4628-33.
14. Kenny-Walsh E for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Eng J Med 1999; 340: 1228-33.
15. Wiese M, Berr F, Lafrenz M, Porst H, Olsen V. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-6.
16. Vogt M, Lay T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Eng J Med 1999; 341: 866-70.
17. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971-1975. Hepatology 2000; 32: 582-7.
18. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmokinetics studies. Hepatology 2002; 36: 993-1000.
19. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-44.
20. Farci P, Strazzera R, Alter HJ, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002; 99: 3081-6.
21. Booth JCL, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobuolinemic patients. Hepatology 1998; 26: 223-7.
22. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C infection. Lancet 1995; 346: 1006-7.
23. Ferrari C, Valli A, Galati L, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-95.
24. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-14.
25. Tsai S, Liaw Y, Chen M, Huang C, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-58.
26. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-58.
27. Cooper S, Erikson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-49.
28. Cucchiarini M, Kammer AR, Grabscheid B, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 2000; 203: 111-23.
29. Chang KM, Gruener NH, Southwood S, et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 1999; 162: 1156-64.
30. Gruner NH, Gerlach TJ, Jung MC, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528-36.
31. Urbani S, Boni C, Missale G, et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002; 76: 12423-34.
32. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl.): S35-46.
33. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31: 17-24.
34. Freeman AJ, Dore GJ, Law MJ, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
35. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997; 349: 825-32.
36. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
37. Pradat R, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C : A European Collaborative Study. Hepatology 2002; 36: 973-7.
38. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-9.
39. Pol S, Lamorthe V, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28: 945-50.
40. Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion associated-hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120-4.
41. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002; 9: 235-41.
42. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
43. Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-91.
44. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-53.
45. Soto B, Sanchez-Quijano A, Rodrigo L. et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
46. Romeo R, Rumi MG, Donato MF, et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepatitis 2000; 7: 297-301.
47. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 1193-9.
48. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
49. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
50. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabete mellitus, and alcohol. Hepatology 2002; 36: 729-36.
51. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
52. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248-52.